7 hours agoOBS: Remdesiviritri is not recommended for patients with COVID-19, evidence of positive effect
Periskopi(6 years ago)
(6 years ago)A panel of the World Health Organization said on Friday that the Remdesiviri medicine is not recommended for hospitalised patients with COVIID-19, no matter how sick they are, because there is no evidence that it improves survival rates or that reduces the need for ventilator use. “Panel found lack of evidence that Remdesiviviri improves [...]
“Paneli found lack of evidence that Remdesiviriviri improves the results that matter to patients, such as reducing mortality, the need for mechanical ventilation, time for clinical improvement, and others”, is said in the organisation's direction.
The OBS Group for Development and Education panel said its recommendation is based on reviewing evidence involving data from four international tests on more than 7,000 patients with COVID-19.
This news is another step back for the now famous substance, which received global attention as the possible drug for treating COVID-19 in the summer after the first tests gave some hope, writes ReutersReport Express.
At the end of October, Remdesivirier's producer, the company “Gilead”, lowered the forecast to enter in during 2020, citing the slightest demand than expected and the difficulties in predicting sales of this substance.
Antiviral medicine is one of two drugs now authorized for the treatment of coronary worldwide, but a large test, led by the OBS, testified last month that Remdesivirivirivir has little or no effect on the mortality rate or on hospital stay of patients with COVID-19.
Remdesiviviri has also been used to treat outgoing U.S. president Donald Trump, and past studies have found to cut patients ' time short. This drug is authorized for use as a treatment against coronary in over 50 countries.
